, Oct. 21
/PRNewswire/ -- Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent (http://www.altogen.com/mirna.php
) in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules RNA, DNA, and small proteins. The company also offers custom encapsulation of target molecules into PEG-liposome in vivo transfection reagent.
Transfection is one of the major laboratory methods used to introduce DNA and RNA molecules into cells and tissues. This technique makes it possible to cross the cellular barriers and deliver a gene or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.
Novel PEGylated liposome-based siRNA delivery kit is optimized for directed RNAi induction by efficient delivery of functional small RNA molecules (siRNA, shRNA, miRNA) into tissues. Liposome component provides in vivo siRNA protection due to efficient siRNA-liposome encapsulation. A remarkable feature of this reagent is reduced innate immune response and low cytotoxicity due to biodegradable PEG modification.
Altogen Biosystems (www.altogen.com) has previously developed nanoparticle-, polymer- and lipid-based in vivo transfection systems (www.altogen.com/mirna.htm) used for laboratory testing pharmaceuticals in cells and animals.
Altogen Biosystems is focusing on commercializing pharma- and bio-technologies, as well as providing custom laboratory services. The company offers pre-clinical contract research services (CRO) including Pharmacology/Toxicology studies, assay development, molecular and cell biology services, development of stable cell lines, gene silencing and complete RNAi services (www.altogenservices.com).
Link: Altogen In Vivo Transfection Reagents: http://www.altogen.com/mirna.php
SOURCE Altogen Biosystems